GLPwatch

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

NCT04067999 · Completed

Last updated 2026-05-28

This study is testing how the medication semaglutide affects people with type 2 diabetes in Spain as part of their regular medical care.

Status Completed The study has finished.
Type Observational
Participants 230 people
Who can join Ages 18+ · all sexes
Timeline Started 2019-08 · est. completion 2021-07
Where 16 sites · Spain

What this study is testing ClinicalTrials.gov NCT04067999 ↗

Description as written by the study sponsor.

The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed to them by their doctor. The study will last for about 6 to 8 months. Participants will be asked to complete some questionnaires about their health and diabetes treatment. Participants will complete these during their normally scheduled visits with their doctor.

Treatments tested

Main thing measuredChange in Glycated Haemoglobin A1c (HbA1c) (measured in percent)
SponsorNovo Nordisk A/S
Conditions studiedDiabetes Mellitus, Type 2
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04067999 ↗